Results 61 to 70 of about 657,649 (153)

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

TPM3–NTRK1 Fusion-Positive Thoracic Sarcoma: Integrated Diagnosis and Drug Repurposing

Indian Journal of Medical and Paediatric Oncology
Poorly differentiated or unclassifiable sarcomas may harbor targetable molecular alterations, and next-generation sequencing is valuable for an integrated diagnosis.
Kinjal Singh, Sameer Rastogi, Santhosh Kumar KN, Deepali Jain, Yamini Dharmashaktu   +4 more
doaj   +1 more source

Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management

MedComm, Volume 7, Issue 10, October 2026.
Colorectal cancer is a heterogeneous, adaptive disease shaped by population‐level risk, genomic and epigenetic alterations, tumor ecosystem evolution, and treatment pressure. This review integrates epidemiology, risk factors, signaling networks, clinical presentation, screening, molecular diagnosis, and stage‐ and biomarker‐guided management while ...
Kairui Wan, Ke Tang, Linglong Wang, Qin Tian, Mingwei Zheng, Cheng Qian, Limei Liu   +6 more
wiley   +1 more source

(R)‑2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors

, 2015
Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types.
Jianwei Che (584881), Valentina Molteni (772022), Auzon Steffy (1601650), Pamela Albaugh (1601671), Celine Tompkins (1601659), Tove Tuntland (1285806), Min Lu (238723), Nanxin Li (672564), Allen Li (1601653), Andreas Kreusch (1601689), Yong Jia (1601683), Guoxun Liu (1601656), Jie Li (15030), Paul V. Rucker (1601674), Yi Fan (285912), Fangxian Sun (1601665), Susan McCormack (280368), Ha-Soon Choi (1601668), Zhicheng Wang (453756), Greg Chopiuk (1601680), Van Phung (237234), Tami Hood (1601692), Bo Liu (127343), Apurva Chaudhary (1601677), Francois Gessier (1541887), AnneMarie Culazzo (1601686), Francisco Adrian (1601695), Mahavir Prashad (1601647), Jon Loren (1601662), Bin Hu (122268), Jennifer Harris (827076), H. Martin Seidel (762811)   +31 more
core   +1 more source

A De Novo Peptide That Induces Axonal Growth Through TrkB Activation

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
A homodimeric anti‐TrkB macrocyclic peptide, DiTrbL3, originally discovered by the RaPID system as monomeric form, dimerizes the TrkB receptor and activate the downstream signaling. DiTrbL3 acts as a mimic of BDNF (the natural protein ligand) and stimulates hippocampal neurons to extend axons.
Rumit Maini, Kota Tamada, Kunihiro Fukuda, Toru Takumi, Hiroaki Suga   +4 more
wiley   +1 more source

Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations

, 2021
NTRK chromosomal rearrangements yield oncogenic TRK fusion proteins that are sensitive to TRK inhibitors (larotrectinib and entrectinib) but often mutate, limiting the durability of response for NTRK(+) patients.
Zhai, Dayong, Zhang, Xin, Chen, Xi, Rogers, Evan, Graber, Armin, Drilon, Alexander, Sprengeler, Paul A, Sprengeler, Paul A., Stopatschinskaja, Shanna, Reich, Siegfried H, Murray, Brion W, Reich, Siegfried H., Besse, Benjamin, Solomon, Benjamin, Murray, Brion W., Deng, Wei   +15 more
core   +2 more sources

Design, Synthesis, and Evaluation of 3,5-Disubstituted 7-Azaindoles as Trk Inhibitors with Anticancer and Antiangiogenic Activities

, 2016
Tropomyosin-related kinase A (TrkA) is considered a promising target in the development of a therapeutic treatment of cancer and pain. In this study, we designed and synthesized a series of novel 7-azaindole-based Trk kinase inhibitors through the ...
Ju Hyeon Seo (2074024), Sungwoo Hong (605716), Seunghee Hong (1817410), Kyung Hee Jung (229409), Jinhee Kim (233831), Soon-Sun Hong (229419)   +5 more
core   +1 more source

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

, 2020
TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or ...
Drilon, Alexander, Hyman, David M, Scaltriti, Maurizio, Shifman, Sophie, Goldman, Debra A, Kundra, Ritika, Bardelli, Alberto, Benayed, Ryma, Rosen, Ezra Y, Schram, Alison M, Taylor, Barry S, Iasonos, Alexia, Cocco, Emiliano, Gong, Yixiao, Hechtman, Jaclyn F, Solomon, James P   +15 more
core   +1 more source

More Than a Birthmark? A Growing Pediatric Skin Lesion

JEADV Clinical Practice, EarlyView.
Shatha Ahmad Al Hajjaj, Sara Al Janahi, Shaden Abdelhadi   +2 more
wiley   +1 more source

Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Neuroendocrine neoplasms, which occur throughout the human body, as well as adrenocortical carcinoma and pheochromocytoma, which originate in the adrenal gland, are primarily classified as rare malignancies. Immunotherapy, including immune checkpoint inhibitors (ICIs), is generally not incorporated into the standard care protocols for these ...
Akihiro Ohmoto, Shunji Takahashi, Shigehisa Kitano   +2 more
wiley   +1 more source